DBV Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.65 |
| 52 Week High | €2.07 |
| 52 Week Low | €0.51 |
| Beta | 0.79 |
| 1 Month Change | -5.28% |
| 3 Month Change | -11.51% |
| 1 Year Change | -57.33% |
| 3 Year Change | -86.88% |
| 5 Year Change | -95.92% |
| Change since IPO | -92.81% |
Recent News & Updates
Recent updates
DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding Up
Oct 24
Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts
Aug 04Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)
Jun 14We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For Now
May 10DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50
May 09Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 14DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 10Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?
Dec 01Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?
Jun 23We're Hopeful That DBV Technologies (EPA:DBV) Will Use Its Cash Wisely
Mar 09Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn Situation
Oct 04DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value Estimate
Aug 06Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash Wisely
Mar 14Shareholder Returns
| DBV | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -15.2% | -0.5% | 2.1% |
| 1Y | -57.3% | -25.6% | -2.4% |
Return vs Industry: DBV underperformed the French Biotechs industry which returned -24.4% over the past year.
Return vs Market: DBV underperformed the French Market which returned -2.8% over the past year.
Price Volatility
| DBV volatility | |
|---|---|
| DBV Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: DBV's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: DBV's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 108 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
| DBV fundamental statistics | |
|---|---|
| Market cap | €62.34m |
| Earnings (TTM) | -€97.12m |
| Revenue (TTM) | €11.91m |
5.2x
P/S Ratio-0.6x
P/E RatioIs DBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBV income statement (TTM) | |
|---|---|
| Revenue | US$12.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$12.52m |
| Other Expenses | US$114.60m |
| Earnings | -US$102.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 100.00% |
| Net Profit Margin | -815.73% |
| Debt/Equity Ratio | 0% |
How did DBV perform over the long term?
See historical performance and comparison